<?xml version="1.0" encoding="UTF-8"?>
<p id="Par38">Immunotherapy has become an innovative technology for lung cancer therapy with the discovery of immunological checkpoints. It has shown great potential in a variety of advanced cancer treatments [
 <xref ref-type="bibr" rid="CR83">83</xref>]. Drug binds to PD-1 molecule and generate steric hindrance that prevents PD-L1 from binding to PD-1 molecule, activates the immune response of PD-1 pathway-mediated, including anti-tumor immune response [
 <xref ref-type="bibr" rid="CR84">84</xref>]. We suggest that for lung cancer patients who receiving immunotherapy during the epidemic, it is not urgent to receive immunotherapy on a set date. Considering the adverse events of pulmonary event caused by immunotherapeutic drugs, immunotherapy can be suspended or postponed in patients with stable disease.
</p>
